cagrilintide and retatrutide vs for Weight Loss Metabolic Health Retatrutide vs CagriSema: The Battle

(2025) T2DM: 47.3% reinitiated GLP-1 therapy within 1 year of discontinuation 57.3% reinitiated within 2 years Without T2DM: 36.3% reinitiated within 1 year 46.4% reinitiated within 2 years Key Factors Linked to Reinitiation: Patients age 65 years Less likely to reinitiate Weight regain after discontinuation Higher likelihood of restarting therapy Moderate to severe GI side effects during initial treatment Lower likelihood of reinitiation Main Takeaway: Most patients who initiated GLP-1 therapy stopped within one year, with higher discontinuation rates among those without T2DM

And the FDA is investigating

The protein primary sequence of CPT1C is larger (798 amino acids) than the two other isoforms

The retatrutide peptide dosage chart gives you pre-calculated unit values for every dose tier across common vial sizes